中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2009年
23期
1333-1335,1339
,共4页
陈萍%李炳宗%王盼君%傅晋翔
陳萍%李炳宗%王盼君%傅晉翔
진평%리병종%왕반군%부진상
原发结外淋巴瘤%原发胃肠道淋巴瘤%诊断%治疗
原髮結外淋巴瘤%原髮胃腸道淋巴瘤%診斷%治療
원발결외림파류%원발위장도림파류%진단%치료
Primary extranodal lymphoma%Primary gastrointestinal non-Hodgkin's lymphoma%Diagnosis%Treatment
目的:探讨原发结外非霍奇金淋巴瘤(PE-NHL)的发病情况、临床特点、诊断及治疗.方法:回顾性分析苏州大学附属第二医院2001年1月～2008年5月收治的PE-NHL 110例.结果:110例PE-NHL占同期收治恶性淋巴瘤患者的60.11%(110/183);原发部位广泛,常见部位依次为胃肠道21.82%(24/110)、Waldeye环10.91%(12/110)、鼻腔和软组织各9.10%(10/110)、纵隔7.27%(8/110)、其他少见部位41.82%(46/110);首发表现以原发器官肿大或肿块为主(77.27%),无特异性;90例患者国际预后指教(IPI)评分:低、中、高危组分别占41.11%、44.44%、14.44%.93例进行免疫分型:B细胞型69.90%,T细胞型30.10%;95例接受治疗,CR 61.05%,PR 16.84%,总有效率77.89%,中位生存时间30个月(2～86个月),5年总生存率27%.24例原发胃肠道非霍奇金淋巴瘤(PGIL),其临床特征与非原发胃肠道组比较无统计学差异,治疗23例,CR 65.21%,PR 17.39%,总有效率82.60%,中位生存时间24个月(2～78个月),5年总生存率30%.结论:本组资料中PE-NHL比例高达60.11%,超过结内淋巴瘤;其首发部位广泛,临床表现多样但无特异性;全面认识本病、遵循合理的诊治模式是提高疗效的关键.
目的:探討原髮結外非霍奇金淋巴瘤(PE-NHL)的髮病情況、臨床特點、診斷及治療.方法:迴顧性分析囌州大學附屬第二醫院2001年1月～2008年5月收治的PE-NHL 110例.結果:110例PE-NHL佔同期收治噁性淋巴瘤患者的60.11%(110/183);原髮部位廣汎,常見部位依次為胃腸道21.82%(24/110)、Waldeye環10.91%(12/110)、鼻腔和軟組織各9.10%(10/110)、縱隔7.27%(8/110)、其他少見部位41.82%(46/110);首髮錶現以原髮器官腫大或腫塊為主(77.27%),無特異性;90例患者國際預後指教(IPI)評分:低、中、高危組分彆佔41.11%、44.44%、14.44%.93例進行免疫分型:B細胞型69.90%,T細胞型30.10%;95例接受治療,CR 61.05%,PR 16.84%,總有效率77.89%,中位生存時間30箇月(2～86箇月),5年總生存率27%.24例原髮胃腸道非霍奇金淋巴瘤(PGIL),其臨床特徵與非原髮胃腸道組比較無統計學差異,治療23例,CR 65.21%,PR 17.39%,總有效率82.60%,中位生存時間24箇月(2～78箇月),5年總生存率30%.結論:本組資料中PE-NHL比例高達60.11%,超過結內淋巴瘤;其首髮部位廣汎,臨床錶現多樣但無特異性;全麵認識本病、遵循閤理的診治模式是提高療效的關鍵.
목적:탐토원발결외비곽기금림파류(PE-NHL)적발병정황、림상특점、진단급치료.방법:회고성분석소주대학부속제이의원2001년1월～2008년5월수치적PE-NHL 110례.결과:110례PE-NHL점동기수치악성림파류환자적60.11%(110/183);원발부위엄범,상견부위의차위위장도21.82%(24/110)、Waldeye배10.91%(12/110)、비강화연조직각9.10%(10/110)、종격7.27%(8/110)、기타소견부위41.82%(46/110);수발표현이원발기관종대혹종괴위주(77.27%),무특이성;90례환자국제예후지교(IPI)평분:저、중、고위조분별점41.11%、44.44%、14.44%.93례진행면역분형:B세포형69.90%,T세포형30.10%;95례접수치료,CR 61.05%,PR 16.84%,총유효솔77.89%,중위생존시간30개월(2～86개월),5년총생존솔27%.24례원발위장도비곽기금림파류(PGIL),기림상특정여비원발위장도조비교무통계학차이,치료23례,CR 65.21%,PR 17.39%,총유효솔82.60%,중위생존시간24개월(2～78개월),5년총생존솔30%.결론:본조자료중PE-NHL비례고체60.11%,초과결내림파류;기수발부위엄범,림상표현다양단무특이성;전면인식본병、준순합리적진치모식시제고료효적관건.
Objective: To evaluate the incidence, clinical features, diagnosis and treatment of primary ex-tranodal non-Hodgkin' s lymphoma (PE-NHL). Methods: The data of 110 patients diagnosed as PE-NHL be-tween January 2001 and May 2008 were reviewed. Results: These PE-NHL patients counted 60.11% of the 183 malignant lymphoma patients at the same period. The primary sites affected were the gastrointestinal tract 21.82% (24/110), Waldeyer ring 10.91% (12/110), nasal cavity 9.10% (10/110), soft tissue 9.10% (10/110), mediastinum 7.27% (8/110) and other unusual sites 41.82% (46/110). Symptoms and signs of PE-NHL were not specific, and 77.27% of these cases had a swelling organ or lump of the primary organ affected. Ac-cording to the International Prognosis Index (IPI), the percentage of patients in low, intermediate, and high group was 41.11%, 44.44% and 14.44%, respectively. Immunophenotype was assayed in 93 cases. The per-centage of B-cell lymphoma was 69.90% while that of T-cell lymphoma was 30.10%. For those 95 cases treat-ed, the effective rate including complete remission (61.05%) and part remission (16.84%) was 77.89%, the median survival was 30 months, and the 5-year overall survival (OS) was 27%. While, for patients with prima-ry gastrointestinal non-Hodgkin' s lymphomas (PGIL), the complete remission rate, part remission rate and the effective rate was 65.21%, 17.39% and 82.80%, respectively. The median survival was 24 months, and the 5-year overall survival (OS) was 30%. Conclusion: PE-NHL is more common than nodal lymphoma. The symptoms and signs of PE-NHL of different sites are quite different. To improve the curative strategies of PE-NHL, it is important to make an allround understanding of PE-NHL and follow reasonable mode of diagno-sis and therapy.
